N/A N=50 The Right Ventricular Pulmonary Circulation Continuum in Mitral Valve Disease Study
Mitral Regurgitation · Pulmonary Hypertension
Primary: Impaired Post-operative Functional Capacity — 35 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=90 Transcatheter Valve Implantation in Patients With Dysfunctional Left and Right Sided Heart Valves
Eisenmenger Syndrome
Primary: Number of Participants Who Developed Infective Endocarditis — 9 participants
N/A N=106 Validation of Naevia Medical in Valvulopathies
Heart Valve Disease
Primary: Number of Relevant Appropriate Recommendations — 2.35; 6.20 Recommendations
N/A N=60 Hemodynamic Comparison of Tissue Aortic Valves
Aortic Valve Stenosis
Primary: Aortic Valve Mean Gradient (mm Hg) at Peak Exercise — 11; 14; 11 mm Hg
N/A N=756 Clinical Investigation Of The Mitroflow Aortic Pericardial Heart Valve
Heart Valve Diseases
Primary: Incidence Rate of Adverse Events and Mortality for the Mitroflow Aortic Heart Valve Repair — 7.1; 1.27; 0.21; 0.56 Percent occurrence per patient-year
Phase 2 N=251 Comparing the Effectiveness of Repairing Versus Replacing the Heart's Mitral Valve in People With Severe Chronic Ischemic Mitral Regurgitation
Mitral Valve Insufficiency · Coronary Artery Disease
Primary: Degree of Left Ventricular Remodeling, as Assessed by Left Ventricular End Systolic Volume Index (LVESVI) — 54.6; 60.7 ml per square meter of body-surface area — p=0.18
N/A N=88 Behavior of Valve Leaflets Following Aortic Valve Implant
Aortic-valve Replacement
Primary: Reduction in Leaflet Motion — 12 Participants
Phase 2 N=23 A Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification
Aortic Valve Stenosis
Primary: Changes in Aortic Valve Calcium Levels — 65; 215 Arbitrary Units — p=0.05
N/A N=283 Carpentier-Edwards PERIMOUNT Magna Ease Pericardial Bioprosthesis, Model 3300TFX
Coronary Artery Disease · Aortic Valve Disorder · Heart Failure
Primary: Subject's Percentage of Long Term Safety Performance — 1.5; 2.7; 0.2; 0.4 Percentage of events/late patient years
N/A N=84 Patients Perception of Mechanical Heart Valve Sounds: Psychoacoustics and Quality of Life
Heart Valve Diseases
Primary: Intensity (Highness) of the Sound From Mechanical Heart Valves — 43; 41; 40 dB (decibel) — p=<0.05
N/A N=208 Minimally Invasive or Conventional Edge-To-Edge Repair for Severe Mitral Regurgitation Due to Bileaflet Prolapse in Barlow's Disease: Does the Surgical Approach Have an Impact on the Long-term Results?
Barlow's Disease · Prolapse; Mitral
Primary: Cardiac Death — 3.9; 3.8 percentage of participants with event
Phase 2 N=55 Feasibility Study of a Percutaneous Mitral Valve Repair System.
Mitral Valve Insufficiency · Mitral Valve Regurgitation · Mitral Valve Incompetence
Primary: Mitral Regurgitation Severity — 0.0; 0.0; 5.6; 38.9 Percentage of participants
N/A N=401 Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery
Mild Tricuspid Regurgitation · Moderate Tricuspid Regurgitation · Tricuspid Regurgitation
Primary: Percentage of Participants With Treatment Failure — 10.2; 3.9 percentage of participants
N/A N=128 Inflammation and the Heart
Rheumatoid Arthritis
Primary: Left Ventricular Mass Indexed to BSA, g/m^2 — 43.8; 42.2 g/m^2
N/A N=225 A Retrospective Study to Collect the Data From the Patients Who Had the Perimount Heart Valve Replacement Surgery in China During 2001 to 2007
Mitral Valve or Aortic Valve Replacement
Primary: The Performance Evaluation of Perimount Heart Valve(Type:6900P and 2900) by Echocardiography — 100; 54.54; 26.51; 81.33 Percentage of all subjects
N/A N=983 Safety Assessment of Angioplasty Procedures
Angiospastic; Disorder
Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants
N/A N=297 Aortic or Mitral Valve Replacement With the Biocor and Biocor Supra
Aortic Valve Insufficiency · Aortic Valve Regurgitation · Aortic Valve Stenosis
Primary: Number of Participants With Adverse Events — 6; 14; 53; 10 participants
N/A N=151 Systemic Lupus Erythematous and Heart Conduction Disorders
Lupus Erythematosus, Systemic · Atrioventricular Block · Sudden Death
Primary: Presence of Conduction Disorders in Patients With SLE Regarding to Its Serologic Profile — 89.22; 91.41; 145.68; 146.72 msec
N/A N=634 CoreValve® System Australia/New Zealand Clinical Study
Aortic Valve Stenosis
Primary: Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) Rate — 0.099 probability of events at 30 days
N/A N=16 HAART Model 300 Annuloplasty Ring
Aortic Regurgitation
Primary: Primary Safety Outcome Measure: Event-free Survival — 100 percentage of participants
N/A N=86,939 The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events
Parkinson's Disease · Hyperprolactinemia
Primary: Number of Participants With Fibrotic Valvular Heart Disease Per 10,000 Participant-Years of Follow-Up — 21; 21; NA; 52 Participants/10,000 Participant-Years
N/A N=934 Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve
Aortic Valve Stenosis · Aortic Valve Stenosis With Insufficiency · Regurgitation, Aortic Valve
Primary: Number of Late Adverse Events Divided by Late Patient Years (Expressed as a Percentage) for the INTUTY Valve Implanted Cohort — 3.9; 0.9; 0.6; 0.3 Percentage of…
N/A N=140 Comparison of Two Pericardial Bioprostheses in AVR
Aortic Valve Disease
Primary: Transvalvular Mean Pressure Gradient (mPG) — 14.1; 13.9 mmHg — p=0.0004
N/A N=16 Early Diagnosis of Diastolic Dysfunction and Reliability of DSE in Detecting Stress Diastolic Dysfunction
Diastolic Dysfunction
Primary: Change in Left Ventricle Mean Diastolic Pressure — 3.3 mmHg
N/A N=39 Magna Mitral - 23mm
Mitral Heart Valve Disease
Primary: Percent of Early Adverse Events Divided — 8.3; 0.0; 0.0; 0.0 percentage of subjects
N/A N=100 EDWARDS INTUITY Valve System CADENCE-MIS Study
Aortic Valve Disease · Aortic Stenosis
Primary: Median Subject Time Spent on Cardiopulmonary Cross Clamp — 35.0; 47.5 Minutes — p=<0.0001
N/A N=116 COronary and MICrocirculatory Measurements in Patients With Aortic Valve Stenosis.
Aortic Stenosis · Coronary Artery Disease
Primary: FFR 6 Months After SAVR/TAVI. — -0.0279 ratio
N/A N=191 Expanded Clinical Study of the Tendyne Mitral Valve System
Mitral Valve Regurgitation
Primary: Safety Endpoint: Number of Participants With Composite of Device Success and Freedom From Device or Procedure Related Serious Adverse Events (SAEs) — 120 Participants
N/A N=120 EDWARDS INTUITY Valve System CADENCE Study
Aortic Valve Disease · Aortic Stenosis
Primary: Average Subject Time Spent on Cardiopulmonary Cross Clamp — 77.5; 82.0 Minutes — p=0.3660
N/A N=280 EDWARDS INTUITY Elite Valve System
Aortic Valve Disease · Aortic Stenosis
Primary: Subject's Average Time Spent on Cardiopulmonary Cross Clamp — 49.9; 65.2; 51.9 minutes